AAS
SVA

Ameritas Advisory Services’s Sinovac Biotech, Ltd SVA Stock Holding History

Ameritas Advisory Services’s Portfolio SVA Stock Details SVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-3
Closed – – 2998
2025
Q2 		$0 Buy
+3
New – ﹤0.01% 2857

Other funds holding SVA

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NAH
Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Horizon Investments Charlotte, North Carolina $8.92B AUM 25.62% 1-Year Est. Return

Ameritas Advisory Services's SVA Position: Q3 2025 in Review

Ameritas Advisory Services sold out of Sinovac Biotech, Ltd (SVA) in Q3 2025, closing a stake of 3 shares.

Ameritas Advisory Services first reported a position in SVA in Q2 2025 and held it in 1 quarter. The position peaked at $0 in Q2 2025. 27 funds tracked by Wall St. Rank hold SVA as of Q3 2025.

  • Ameritas Advisory Services reported no remaining Sinovac Biotech, Ltd position as of Q3 2025 after selling out during the quarter.
  • Ameritas Advisory Services sold 3 Sinovac Biotech, Ltd shares in Q3 2025.
  • Ameritas Advisory Services first reported a position in Sinovac Biotech, Ltd in Q2 2025 and held it in 1 quarter.
  • Ameritas Advisory Services's Sinovac Biotech, Ltd position peaked at $0 in Q2 2025.
  • 27 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q3 2025.

Based on Ameritas Advisory Services's 13F filing for Q3 2025, filed 6 Nov 2025.